Product Description
ÊVorolanib (CM082) is a multi-target tyrosine kinase inhibitor including VEGF, PDGF, c-kit, and Flt-3. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.10040)
Mechanisms of Action: VEGFR Inhibitor,PGFR Inhibitor,CSF-1R Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AnewPharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Thoracic Cancer|Thymoma|Wet Macular Degeneration
Phase 1: Acute Myeloid Leukemia|Acute Respiratory Distress Syndrome|Gastrointestinal Cancer|Healthy Volunteers|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VICC THO 1802 | P2 |
Active, not recruiting |
Thoracic Cancer|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Thymoma |
2024-02-21 |
|
| CM082-CA-I-105 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2023-06-01 |
25% |
| CM082-CA-I-109 | P1 |
Completed |
Acute Respiratory Distress Syndrome |
2021-10-22 |
28% |
| CTR20182458 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2020-01-16 |